Armata Pharmaceuticals Inc

(NYSE MKT:ARMP)

Latest On Armata Pharmaceuticals Inc (ARMP):

Date/Time Type Description Signal Details
2023-05-12 06:30 ESTNewsArmata Pharmaceuticals GAAP EPS of -$0.40, revenue of $0.79MN/A
2023-03-17 05:49 ESTNewsArmata Pharmaceuticals GAAP EPS of -$0.29 misses by $0.01, revenue of $1.05M misses by $0.62MN/A
2023-03-06 11:05 ESTNewsArmata surges 15% as inhaled bacterial infection drug shows promise in lung disorder patientsN/A
2022-11-09 20:41 ESTNewsArmata Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04, revenue of $1.34M misses by $0.32MN/A
2022-08-11 23:11 ESTNewsArmata Pharmaceuticals GAAP EPS of -$0.26, revenue of $1.88MN/A
2022-08-01 22:21 ESTNewsFDA clears Armata Pharma's application for its treatment for prosthetic joint infectionN/A
2022-05-13 07:30 ESTNewsArmata Pharmaceuticals GAAP EPS of -$0.30 misses by $0.09, revenue of $1.24M beats by $0.26MN/A
2022-03-18 12:30 ESTNewsArmata Pharmaceuticals GAAP EPS of -$0.23 beats by $0.05, revenue of $0.99MN/A
2022-02-10 03:55 ESTNewsArmata Pharmaceuticals announces $45M investment by InnovivaN/A
2021-11-19 07:47 ESTNewsArmata Pharma up 8% on FDA acceptance of IND application for antibioticN/A
2021-11-11 01:35 ESTNewsArmata Pharmaceuticals EPS beats by $0.04, beats on revenueN/A
2021-10-12 20:52 ESTNewsWarning: ARMP is at high risk of performing badlyN/A
2021-10-07 05:19 ESTNewsARMP is at high risk of performing badlyN/A
2021-09-27 13:12 ESTNewsWarning: ARMP has been downgraded to Very BearishN/A
2021-09-22 21:51 ESTNewsWarning: ARMP has been downgraded to Very Bearish.N/A
2021-08-13 09:12 ESTNewsArmata Pharmaceuticals EPS beats by $0.02, beats on revenueN/A
2021-08-02 12:55 ESTNewsArmata Pharma CEO steps downN/A
2021-03-19 13:39 ESTNewsArmata Pharmaceuticals EPS misses by $0.08, beats on revenueN/A
2021-03-19 04:13 ESTEarnings EstimateAn EPS average of -$0.61 is estimated for the 2022 year.Sell
2021-03-19 04:13 ESTEarnings EstimateAn EPS average of -$0.15 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-17 18:54 ESTNewsArmata closes second and final tranche of $20M private placement with InnovivaN/A
2021-01-27 12:01 ESTNewsArmata announces capital raise of $20MN/A
2020-12-13 03:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 19:09 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 03:09 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 03:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $7.75 to $7.25.Neutral
2020-11-15 11:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 11:14 ESTEarnings EstimateAn EPS average of -$0.22 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-12 17:36 ESTNewsArmata Pharmaceuticals EPS misses by $0.06, misses on revenueN/A
2020-11-01 17:06 ESTFinancialsCompany financials have been released.Neutral
2020-10-15 10:46 ESTNewsArmata Pharma on go with mid-stage study of AP-PA02 in pseudomonas aeruginosa infectionsN/A
2020-09-26 04:17 ESTFinancialsCompany financials have been released.Neutral
2020-08-15 16:09 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 13:23 ESTNewsArmata Pharmaceuticals EPS beats by $0.09N/A
2020-07-31 00:12 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 12:09 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:16 ESTFinancialsCompany financials have been released.Neutral
2020-06-18 06:15 ESTNewsArmata Pharma nabs $15M DoD award to treat S. aureus bacteremia infectionsN/A
2020-06-02 16:18 ESTEarnings EstimateAn EPS average of -$0.40 is estimated for the quarter ending on September 30, 2020.Buy
2020-06-02 16:18 ESTAnalyst RatingThe Analyst Target Price has decreased from $8.75 to $7.75.Neutral
2020-05-31 16:35 ESTFinancialsCompany financials have been released.Neutral
2020-05-20 12:17 ESTFinancialsCompany financials have been released.Neutral
2020-05-15 16:12 ESTNewsArmata Pharmaceuticals EPS misses by $0.18N/A
2020-05-10 09:03 ESTNewsArmata Pharmaceuticals (ARMP) Investor Presentation - SlideshowN/A
2020-05-04 12:09 ESTFinancialsCompany financials have been released.Neutral
2020-05-03 08:10 ESTFinancialsCompany financials have been released.Neutral
2020-04-30 08:08 ESTFinancialsCompany financials have been released.Neutral
2020-04-11 02:20 ESTNewsArmata Pharma nabs $5M award to support AP-PA02 study; shares up 8%N/A
2020-04-11 02:19 ESTNewsArmata Pharmaceuticals EPS beats by $0.15N/A
2020-04-11 02:08 ESTNewsAramata Pharma files for $100M mixed shelfN/A

About Armata Pharmaceuticals Inc (ARMP):

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.

ARMP Quotes by TradingView

See Advanced Chart

General

  • Name Armata Pharmaceuticals Inc
  • Symbol ARMP
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 33
  • Last Split Factor1:14
  • Last Split Date2019-05-10
  • Fiscal Year EndDecember
  • IPO Date2011-03-09
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.armatapharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 245.15
  • Price/Book (Most Recent Quarter) 4.61
  • Enterprise Value Revenue 347.03
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$0.85
  • Next Year EPS Estimate -$0.61
  • Next Quarter EPS Estimate -$0.19
  • Operating Margin -5908%
  • Return on Assets -31%
  • Return on Equity -94%
  • Revenue 319000
  • Earnings Per Share -$0.14
  • Revenue Per Share $0.02
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 112.52 million
  • EBITDA -11489000
  • Analyst Target Price $7.25
  • Book Value Per Share $1.32
View More

Share Statistics

  • Shares Outstanding 20.61 million
  • Shares Float 8.38 million
  • % Held by Insiders 6312%
  • % Held by Institutions 15.98%
  • Shares Short 58547
  • Shares Short Prior Month 99571
  • Short Ratio 0.6
  • Short % of Float 1%
View More

Technicals

  • 52 Week High $6.39
  • 52 Week Low $2.56
  • 50 Day Moving Average 5.62
  • 200 Day Moving Average 3.82
View More

Dividends

  • Dividend Date 2019-05-10
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Armata Pharmaceuticals Inc (ARMP) Dividend Calendar:

ARMP's last dividend payment was made to shareholders on May 10, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Armata Pharmaceuticals Inc (ARMP) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-17-$0.36-$0.27-33.33%
2020-09-302020-11-12$N/A-$0.31-$0.25-25.25%
2020-06-302020-08-13$N/A-$0.26-$0.3525.71%
2020-03-312020-05-14$N/A-$0.49-$0.31-56.4%
2019-12-312020-03-19$N/A-$0.48-$0.6930.69%
2019-09-302019-11-12$N/A-$0.73-$0.46-60.44%
2019-06-302019-08-14$N/A-$0.56-$0.37-53.42%
2019-03-312019-05-06$N/A-$1.54-$1.561.28%
2018-12-312019-03-25$N/A-$2.10-$0.98-114.29%
2018-09-302018-11-08$N/A-$1.40-$1.400%
2018-06-302018-08-09$N/A-$2.66-$2.805%
2018-03-312018-05-15$N/A-$3.36-$2.66-26.32%
2017-12-312018-03-14-$3.50-$5.0430.56%
2017-09-302017-11-14-$1.26-$6.0279.07%
2017-06-302017-08-14-$16.90
2017-03-312017-05-15-$27.16-$114.8076.34%
2016-12-312017-03-27$0.03-$3.00101%
2016-09-302016-11-10-$3.20-$4.1021.95%
2016-06-302016-08-15-$7.30-$6.60-10.61%
2016-03-312016-05-12-$8.20-$6.80-20.59%
2015-12-312016-03-30-$7.10-$4.00-77.5%
2015-09-302015-11-16-$15.80$0.40-4050%
2015-06-302015-08-13-$5.70-$10.0043%
2015-03-312015-04-15-$1.00$1.50-166.67%
2014-09-302014-11-14-$0.50$2.00-125%
2014-06-302014-09-12$292.06
2014-03-312014-04-15-$420.00-$280.00-50%
2010-03-312010-06-01$593.46
2009-09-302009-11-17$227.43
2009-06-302009-08-13$2,490.58
2009-03-312009-05-08-$612.05
2008-09-302008-11-05-$910.00-$910.000%
2008-06-302008-08-06-$1,330.00-$1,190.00-11.76%
2008-03-312008-05-07-$1,190.00-$2,100.0043.33%
2007-12-312008-03-25-$1,820.00-$1,120.00-62.5%
2007-09-302007-10-31-$1,050.00-$1,820.0042.31%
2007-06-302007-08-07-$2,170.00-$1,190.00-82.35%
2007-03-312007-05-09-$2,100.00-$2,100.000%
2006-12-312007-03-29$560.00-$910.00161.54%
2006-09-302006-11-08-$2,240.00-$1,890.00-18.52%
2006-06-302006-08-10-$19,801.92
2006-03-312006-05-02-$2,944.59
2005-12-312006-03-09-$2,800.00-$4,200.0033.33%
2005-09-302005-11-03-$4,900.00-$4,200.00-16.67%
2005-06-302005-07-28-$4,200.00-$4,200.000%
2005-03-312005-04-26-$3,500.00-$3,850.009.09%
2004-12-312005-03-03-$2,100.00-$3,266.6735.71%
2004-09-302004-11-04-$2,100.00-$3,500.0040%
2004-06-302004-07-29-$3,500.00-$3,500.000%
2004-03-312004-04-28-$4,900.00-$3,500.00-40%
2003-12-312004-03-01-$7,000.00-$4,550.00-53.85%
2003-09-302003-10-30-$700.00-$4,900.0085.71%
2003-06-302003-07-31-$9,100.00-$3,500.00-160%
2003-03-312003-05-06-$1,148.65
2002-12-312003-03-28-$8,397.48
2002-09-302002-09-30-$7,603.64
2002-06-302002-06-30-$10,200.75
2002-03-312002-04-30-$10,500.00-$11,900.0011.76%
2001-12-312002-02-14-$13,300.00-$10,266.67-29.55%
2001-09-302001-11-09-$11,200.00-$10,500.00-6.67%
2001-06-302001-08-14-$9,800.00-$11,200.0012.5%
2001-03-312001-05-10-$7,700.00-$9,800.0021.43%
2000-12-312001-03-02-$9,800.00-$11,900.0017.65%
2000-09-302000-12-15$700.00$700.000%
2000-06-302000-08-09-$8,400.00-$6,650.00-26.32%
2000-03-312000-05-08-$6,300.00-$7,000.0010%
1999-09-301999-09-30-$32,368.25
1999-06-301999-06-30-$13,354.14
1999-03-311999-03-31-$6,127.48
1998-12-311999-02-18$3,500.00-$10,500.00133.33%
1998-09-301998-09-30-$8,097.78
1998-06-301998-06-30-$8,074.57
1998-03-311998-03-31-$13,086.33
1997-06-301997-07-31-$13,300.00-$11,900.00-11.76%
1997-03-311997-05-01-$11,900.00-$11,200.00-6.25%
1996-12-311997-02-13-$11,200.00-$11,900.005.88%
1996-06-301996-08-01-$15,400.00-$18,900.0018.52%
1996-03-311996-05-02-$16,100.00-$17,500.008%
1995-12-311996-02-13-$13,300.00-$9,450.00-40.74%
1995-09-301995-11-02-$13,300.00-$5,600.00-137.5%
1995-06-301995-08-03-$18,900.00-$22,750.0016.92%
1994-12-311995-02-09-$17,500.00-$20,300.0013.79%
1994-09-301994-11-03-$17,500.00-$18,900.007.41%

Armata Pharmaceuticals Inc (ARMP) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Armata Pharmaceuticals Inc (ARMP) Chart:

ARMP chart by TradingView

Armata Pharmaceuticals Inc (ARMP) News:

Below you will find a list of latest news for Armata Pharmaceuticals Inc (ARMP) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Armata Pharmaceuticals Inc (ARMP) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-172.50.05CALL0 201175.85FALSE00
2025-04-1750CALL0 01074.19FALSE00
2025-04-177.50CALL0 01155FALSE00
2025-04-172.50PUT0 0326.13TRUE00
2025-04-1750PUT0 00TRUE00
2025-04-177.50PUT0 00TRUE00
2025-05-162.54.8CALL0 2233.57FALSE00
2025-05-1654.41CALL0 1721.04FALSE00
2025-05-167.50CALL0 0770.93FALSE00
2025-05-162.50.9PUT0 10229.97TRUE00
2025-05-1650PUT0 01193.44TRUE00
2025-05-167.50PUT0 01250.54TRUE00
2025-08-152.50CALL0 0546.3FALSE00
2025-08-1550.6CALL0 1525.79FALSE00
2025-08-157.50.05CALL2 0145.51FALSE0.050
2025-08-152.50PUT0 0197.82TRUE00
2025-08-1550PUT0 0110.01TRUE00
2025-08-157.50PUT0 00TRUE00
2025-11-212.50CALL0 00FALSE00
2025-11-2150CALL0 0630.74FALSE00
2025-11-217.50CALL0 0646.82FALSE00
2025-11-212.50PUT0 0203.23TRUE00
2025-11-2150PUT0 0128TRUE00
2025-11-217.50PUT0 00TRUE00

Latest ARMP Trades:

Date Shares Price
Jun 13, 2022 5:53 PM EST40$4.43
Jun 13, 2022 5:53 PM EST17$4.44
Jun 13, 2022 6:05 PM EST70$4.43
Jun 13, 2022 6:05 PM EST30$4.43

Armata Pharmaceuticals Inc (ARMP) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465920074655/0001104659-20-074655-index.htm
2018-08-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/921114/000000000018026766/0000000000-18-026766-index.htm
2020-04-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/921114/000000000020002968/0000000000-20-002968-index.htm
2020-04-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/921114/000000000020002969/0000000000-20-002969-index.htm
2020-02-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/921114/000089914020000160/0000899140-20-000160-index.htm
2020-03-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/921114/000089914020000223/0000899140-20-000223-index.htm
2019-05-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000089924319013783/0000899243-19-013783-index.htm
2019-05-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000089924319013786/0000899243-19-013786-index.htm
2019-05-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000089924319013788/0000899243-19-013788-index.htm
2019-05-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000089924319013789/0000899243-19-013789-index.htm
2019-05-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000089924319013798/0000899243-19-013798-index.htm
2019-05-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000089924319013800/0000899243-19-013800-index.htm
2019-05-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000089924319013801/0000899243-19-013801-index.htm
2019-05-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000089924319014219/0000899243-19-014219-index.htm
2019-01-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/921114/000090266419000104/0000902664-19-000104-index.htm
2019-05-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000091191619000120/0000911916-19-000120-index.htm
2018-03-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/921114/000091957418002753/0000919574-18-002753-index.htm
2019-10-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000110465919054139/0001104659-19-054139-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000110465919054141/0001104659-19-054141-index.htm
2019-10-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/921114/000110465919055539/0001104659-19-055539-index.htm
2019-10-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/921114/000110465919055541/0001104659-19-055541-index.htm
2019-12-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465919071854/0001104659-19-071854-index.htm
2020-01-09S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/921114/000110465920002355/0001104659-20-002355-index.htm
2020-01-09FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/921114/000110465920002414/0001104659-20-002414-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465920008032/0001104659-20-008032-index.htm
2020-01-30RWRegistration Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/921114/000110465920008324/0001104659-20-008324-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465920020186/0001104659-20-020186-index.htm
2020-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000110465920022091/0001104659-20-022091-index.htm
2020-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000110465920022092/0001104659-20-022092-index.htm
2020-02-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000110465920022095/0001104659-20-022095-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000110465920022097/0001104659-20-022097-index.htm
2020-02-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000110465920022124/0001104659-20-022124-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000110465920022126/0001104659-20-022126-index.htm
2020-02-21PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/921114/000110465920023874/0001104659-20-023874-index.htm
2020-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465920025375/0001104659-20-025375-index.htm
2020-03-06DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/921114/000110465920030188/0001104659-20-030188-index.htm
2020-03-06DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/921114/000110465920030191/0001104659-20-030191-index.htm
2020-03-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465920035845/0001104659-20-035845-index.htm
2020-03-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465920035846/0001104659-20-035846-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465920040578/0001104659-20-040578-index.htm
2020-04-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/921114/000110465920041935/0001104659-20-041935-index.htm
2020-04-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/921114/000110465920041938/0001104659-20-041938-index.htm
2020-04-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/921114/000110465920043792/0001104659-20-043792-index.htm
2020-04-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/921114/000110465920043796/0001104659-20-043796-index.htm
2020-04-09424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/921114/000110465920044834/0001104659-20-044834-index.htm
2020-04-09424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/921114/000110465920044835/0001104659-20-044835-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465920052383/0001104659-20-052383-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000110465920074655/0001104659-20-074655-index.htm
2020-10-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/921114/000110465920117152/0001104659-20-117152-index.htm
2020-10-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/921114/000110465920117160/0001104659-20-117160-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420418028863/0001144204-18-028863-index.htm
2018-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/921114/000114420418028870/0001144204-18-028870-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420418043280/0001144204-18-043280-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/921114/000114420418043320/0001144204-18-043320-index.htm
2018-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420418047924/0001144204-18-047924-index.htm
2018-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420418049740/0001144204-18-049740-index.htm
2018-09-18S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/921114/000114420418049744/0001144204-18-049744-index.htm
2018-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420418052845/0001144204-18-052845-index.htm
2018-10-09S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/921114/000114420418052848/0001144204-18-052848-index.htm
2018-10-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/921114/000114420418052985/0001144204-18-052985-index.htm
2018-10-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/921114/000114420418052986/0001144204-18-052986-index.htm
2018-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420418053309/0001144204-18-053309-index.htm
2018-10-11S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/921114/000114420418053311/0001144204-18-053311-index.htm
2018-10-12POS EXPost-effective amendment adding exhibits to registration statement [Rule 462(d)]https://www.sec.gov/Archives/edgar/data/921114/000114420418053554/0001144204-18-053554-index.htm
2018-10-15424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/921114/000114420418053841/0001144204-18-053841-index.htm
2018-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420418054026/0001144204-18-054026-index.htm
2018-10-26PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/921114/000114420418055579/0001144204-18-055579-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/921114/000114420418058340/0001144204-18-058340-index.htm
2018-11-09DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/921114/000114420418058507/0001144204-18-058507-index.htm
2018-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420418065017/0001144204-18-065017-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419000693/0001144204-19-000693-index.htm
2019-01-04DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/921114/000114420419000694/0001144204-19-000694-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419000775/0001144204-19-000775-index.htm
2019-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419001605/0001144204-19-001605-index.htm
2019-01-14DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/921114/000114420419001606/0001144204-19-001606-index.htm
2019-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419001650/0001144204-19-001650-index.htm
2019-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419005444/0001144204-19-005444-index.htm
2019-03-2510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/921114/000114420419015711/0001144204-19-015711-index.htm
2019-03-25PREM14APreliminary proxy statements relating to merger or acquisitionhttps://www.sec.gov/Archives/edgar/data/921114/000114420419015715/0001144204-19-015715-index.htm
2019-04-04DEFM14ADefinitive proxy statement relating to merger or acquisitionhttps://www.sec.gov/Archives/edgar/data/921114/000114420419018110/0001144204-19-018110-index.htm
2019-04-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/921114/000114420419019677/0001144204-19-019677-index.htm
2019-05-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/921114/000114420419022602/0001144204-19-022602-index.htm
2019-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/921114/000114420419023904/0001144204-19-023904-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419024518/0001144204-19-024518-index.htm
2019-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419025292/0001144204-19-025292-index.htm
2019-05-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/921114/000114420419025339/0001144204-19-025339-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419025762/0001144204-19-025762-index.htm
2019-05-21SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/921114/000114420419027380/0001144204-19-027380-index.htm
2019-05-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/921114/000114420419027442/0001144204-19-027442-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028253/0001144204-19-028253-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028254/0001144204-19-028254-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028255/0001144204-19-028255-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028256/0001144204-19-028256-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028257/0001144204-19-028257-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028258/0001144204-19-028258-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028259/0001144204-19-028259-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028260/0001144204-19-028260-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028261/0001144204-19-028261-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000114420419028262/0001144204-19-028262-index.htm
2019-06-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/921114/000114420419030481/0001144204-19-030481-index.htm
2019-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419032058/0001144204-19-032058-index.htm
2019-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419032469/0001144204-19-032469-index.htm
2019-09-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419044330/0001144204-19-044330-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419045764/0001144204-19-045764-index.htm
2019-10-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000114420419047947/0001144204-19-047947-index.htm
2019-10-11PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/921114/000114420419048128/0001144204-19-048128-index.htm
2019-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/921114/000139382519000009/0001393825-19-000009-index.htm
2019-11-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/921114/000149315219016932/0001493152-19-016932-index.htm
2019-01-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/921114/000153561019000021/0001535610-19-000021-index.htm
2019-07-248-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/921114/000155837019006274/0001558370-19-006274-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/921114/000155837019008168/0001558370-19-008168-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/921114/000155837019010811/0001558370-19-010811-index.htm
2019-12-20S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/921114/000155837019011671/0001558370-19-011671-index.htm
2020-03-1910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/921114/000155837020002943/0001558370-20-002943-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/921114/000155837020006601/0001558370-20-006601-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/921114/000155837020010541/0001558370-20-010541-index.htm
2019-05-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/921114/000156761919011520/0001567619-19-011520-index.htm
2020-01-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/921114/000156761920000921/0001567619-20-000921-index.htm
2020-02-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000156761920003975/0001567619-20-003975-index.htm
2020-03-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/921114/000156761920007226/0001567619-20-007226-index.htm
2018-08-21S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/921114/000157104918000447/0001571049-18-000447-index.htm
2018-10-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/921114/999999999518002592/9999999995-18-002592-index.htm
2020-04-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/921114/999999999520000712/9999999995-20-000712-index.htm
2020-04-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/921114/999999999520000713/9999999995-20-000713-index.htm
2018-07-10CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/921114/999999999718006802/9999999997-18-006802-index.htm

Armata Pharmaceuticals Inc (ARMP) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Armata Pharmaceuticals Inc (ARMP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 6312%
Institutional Ownership: 1598%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-27Innoviva, Inc.10% Share HolderBuy7,717,661.002.8722,149,687.078,710,800.00https://www.sec.gov/Archives/edgar/data/921114/000156761920007226/0001567619-20-007226-index.htm